The class i histone deacetylase inhibitor ms-275 prevents pancreatic beta cell death induced by palmitate

Journal of Diabetes Research

Volumn 2014, Issue , 2014, Pages

  Plaisance, Valérie ^a   Rolland, Laure ^a   Gmyr, Valéry ^b   Annicotte, Jean Sébastien ^a   Kerr Conte, Julie ^b   Pattou, François ^b   Abderrahmani, Amar ^a  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ENTINOSTAT; PALMITIC ACID; ATF3 PROTEIN, HUMAN; ATF3 PROTEIN, MOUSE; BENZAMIDE DERIVATIVE; DDIT3 PROTEIN, HUMAN; DDIT3 PROTEIN, MOUSE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HDAC1 PROTEIN, HUMAN; HDAC1 PROTEIN, MOUSE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENDOPLASMIC RETICULUM STRESS; HUMAN; LIPOTOXICITY; MIN6 CELL LINE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROTECTION; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TISSUE CULTURE TECHNIQUE; TUMOR CELL LINE;

ACTIVATING TRANSCRIPTION FACTOR 3; ANIMALS; APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; CYTOPROTECTION; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; INSULIN-SECRETING CELLS; MICE; PALMITIC ACID; PYRIDINES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TISSUE CULTURE TECHNIQUES; TRANSCRIPTION FACTOR CHOP; TRANSFECTION;

EID: 84921047345     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2014/195739     Document Type: Article

References (49)

1. A. Bonnefond, P. Froguel, and M. Vaxillaire, "The emerging genetics of type 2 diabetes," Trends in Molecular Medicine, vol. 16, no. 9, pp. 407-416, 2010.
2. M. Prentki and C. J. Nolan, "Islet cell failure in type 2 diabetes," The Journal of Clinical Investigation, vol. 116, no. 7,pp. 1802-1812, 2006.
3. M. Y. Donath, M. Böni-Schnetzler, H. Ellingsgaard, P. A. Halban, and J. A. Ehses, "Cytokine production by islets in health and diabetes: Cellular origin, regulation and function," Trends in Endocrinology and Metabolism, vol. 21, no. 5, pp. 261-267, 2010.
4. M. Lundh, D. P. Christensen, M. Damgaard Nielsen et al., "Histone deacetylases 1 and 3 but not 2 mediate cytokineinduced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children," Diabetologia, vol. 55, no. 9, pp. 2421-2431, 2012.
5. D. H.-C. Chou, E. B. Holson, F. F. Wagner et al., "Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis," Chemistry&Biology, vol. 19,no. 6, pp. 669-673,2012.
6. J. Knipstein and L. Gore, "Entinostat for treatment of solid tumors and hematologic malignancies," Expert Opinion on Investigational Drugs, vol. 20, no. 10, pp. 1455-1467, 2011.
7. X. Lin, K. Song, N. Lim et al., "Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic scorethe CoLaus Study," Diabetologia, vol. 52, no. 4, pp. 600-608, 2009.
8. G. Paolisso, P. A. Tataranni, J. E. Foley, C. Bogardus, B. V. Howard, and E. Ravussin, "A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM," Diabetologia, vol. 38, no. 10, pp. 1213-1217, 1995.
9. K. Eguchi, I. Manabe, Y. Oishi-Tanaka et al., "Saturated fatty acid and TLR signaling link cell dysfunction and islet inflammation," CellMetabolism, vol. 15, no. 4, pp. 518-533, 2012.
10. J. J. Meier, T. G. K. Breuer, R. C. Bonadonna et al., "Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans," Diabetologia, vol. 55, no. 5, pp. 1346-1354, 2012.
11. A. E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R. A. Rizza, and P. C. Butler, "-cell deficit and increased -cell apoptosis in humans with type 2 diabetes," Diabetes, vol. 52, no. 1, pp. 102-110, 2003.
12. M. Y. Donath, D. M. Schumann, M. Faulenbach, H. Ellingsgaard, A. Perren, and J. A. Ehses, "Islet inflammation in type 2 diabetes: frommetabolic stress to therapy," Diabetes Care, vol. 31, supplement 2, pp. S161-S164, 2008.
13. M. Dubois, J. Kerr-Conte, V. Gmyr et al., "Non-esterified fatty acids are deleterious for human pancreatic islet function at physiological glucose concentration," Diabetologia, vol. 47, no. 3, pp. 463-469, 2004.
14. D. K. Hagman, L. B. Hays, S. D. Parazzoli, and V. Poitout, "Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing MafA expression in isolated rat islets of Langerhans," Journal of Biological Chemistry, vol. 280, no. 37, pp. 32413-32418, 2005.
15. V. Poitout and R. P. Robertson, "Minireview: secondary -cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity," Endocrinology, vol. 143, no. 2, pp. 339-342, 2002.
16. V. Plaisance,V. Perret,D. Favre et al., "Role of the transcriptional factor C/EBP in free fatty acid-elicited -cell failure," Molecular and Cellular Endocrinology, vol. 305, no. 1-2, pp. 47-55, 2009.
17. S. Kashyap, R. Belfort, A. Gastaldelli et al., "A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes," Diabetes, vol. 52, no. 10, pp. 2461-2474, 2003.
18. M. L. Watson, K. Macrae, A. E. Marley, and H. S. Hundal, "Chronic effects of palmitate overload on nutrient-induced insulin secretion and autocrine signalling in pancreatic MIN6 beta cells," PLoS ONE, vol. 6, no. 10, Article IDe25975, 2011.
19. M. Cnop, L. Ladriere,M. Igoillo-Esteve, R. F. Moura, and D. A. Cunha, "Causes and cures for endoplasmic reticulum stress in lipotoxic -cell dysfunction," Diabetes, Obesity and Metabolism, vol. 12, supplement 2, pp. 76-82, 2010.
20. M. C. Akerfeldt, J. Howes, J. Y. Chan et al., "Cytokine-Induced -cell death is independent of endoplasmic reticulum stress signaling," Diabetes, vol. 57, no. 11, pp. 3034-3044, 2008.
21. I. Kharroubi, L. Ladriere, A. K. Cardozo, Z. Dogusan, M. Cnop, and D. L. Eizirik, "Free fatty acids and cytokines induce pancreatic -cell apoptosis by different mechanisms: role of nuclear factor-B and endoplasmic reticulum stress," Endocrinology, vol. 145, no. 11, pp. 5087-5096, 2004.
22. D. R. Laybutt, A. M. Preston, M. C. Akerfeldt et al., "Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes," Diabetologia, vol. 50, no. 4, pp. 752-763, 2007.
23. D. L. Eizirik, A. K. Cardozo, and M. Cnop, "The role for endoplasmic reticulum stress in diabetes mellitus," Endocrine Reviews, vol. 29, no. 1, pp. 42-61, 2008.
24. Y. Shi, S. I. Taylor, S.-L. Tan, and N. Sonenberg, "When translation meets metabolism: multiple links to diabetes," Endocrine Reviews, vol. 24, no. 1, pp. 91-101, 2003.
25. D. Ron and P. Walter, "Signal integration in the endoplasmic reticulum unfolded protein response," Nature Reviews Molecular Cell Biology, vol. 8, no. 7, pp. 519-529, 2007.
26. H.-Y. Jiang, S. A. Wek, B. C. McGrath et al., "Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response," Molecular and Cellular Biology, vol. 24, no. 3, pp. 1365-1377, 2004.
27. M. G. Hartman, D. Lu, M.-L. Kim et al., "Role for activating transcription factor 3 in stress-induced -cell apoptosis," Molecular and Cellular Biology, vol. 24, no. 13, pp. 5721-5732, 2004.
28. P. Marchetti, M. Bugliani, R. Lupi et al., "The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients," Diabetologia, vol. 50, no. 12, pp. 2486-2494, 2007.
29. E. J. Zmuda, L. Qi,M. X. Zhu, R. G. Mirmira, M. R. Montminy, and T. Hai, "The roles of ATF3, an adaptive-response gene, in high-fat-diet-induced diabetes and pancreatic -cell dysfunction," Molecular Endocrinology, vol. 24, no. 7, pp. 1423-1433, 2010.
30. S. Oyadomari, A. Koizumi, K. Takeda et al., "Targeted disruption of the Chop gene delays endoplasmic reticulum stressmediated diabetes," Journal of Clinical Investigation, vol. 109, no. 4, pp. 525-532, 2002.
31. A. K. Busch, D. Cordery, G. S. Denyer, and T. J. Biden, "Expression profiling of palmitate-and oleate-regulated genes provides novel insights into the effects of chronic lipid exposure on pancreatic -cell function," Diabetes, vol. 51, no. 4, pp. 977-987, 2002.
32. V. Lilla, G. Webb, K. Rickenbach et al., "Differential gene expression in well-regulated and dysregulated pancreatic -cell (MIN6) sublines," Endocrinology, vol. 144, no. 4, pp. 1368-1379, 2003.
33. M. Ferdaoussi, S. Abdelli, J.-Y. Yang et al., "Exendin-4 protects -cells from interleukin-1-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway," Diabetes, vol. 57, no. 5, pp. 1205-1215, 2008.
34. M.-C. Vantyghem, J. Kerr-Conte, L. Arnalsteen et al., "Primary graft function, metabolic control, and graft survival after islet transplantation," Diabetes Care, vol. 32, no. 8, pp. 1473-1478, 2009.
35. D. Favre, E. Le Gouill, D. Fahmi et al., "Impaired expression of the inducible cAMP early repressor accounts for sustained adipose CREB activity in obesity," Diabetes, vol. 60, no. 12, pp. 3169-3174, 2011.
36. H. Ezanno, V. Pawlowski, S. Abdelli et al., "JNK3 is required for the cytoprotective effect of exendin 4," Journal of Diabetes Research, vol. 2014, Article ID 814854, 5 pages, 2014.
37. D. A. Cunha, P. Hekerman, L. Ladriere et al., "Initiation and execution of lipotoxic ER stress in pancreatic -cells," Journal of Cell Science, vol. 121, no. 14, pp. 2308-2318, 2008.
38. E. Sargsyan and P. Bergsten, "Lipotoxicity is glucose-dependent in INS-1E cells but not in human islets and MIN6 cells," Lipids in Health and Disease, vol. 10, article 115, 2011.
39. S. Malmgren, P. Spégel, A. P. H. Danielsson et al., "Coordinate changes in histone modifications,mRNA levels, and metabolite profiles in clonal INS-1 832/13 -cells accompany functional adaptations to lipotoxicity," The Journal of Biological Chemistry, vol. 288, no. 17, pp. 11973-11987, 2013.
40. R. G. Fred, C. H. Bang-Berthelsen, T. Mandrup-Poulsen, L. G. Grunnet, and N. Welsh, "High glucose suppresses human islet insulin biosynthesis by inducing miR-133a leading to decreased polypyrimidine tract binding protein-expression," PLoS ONE, vol. 5, no. 5, Article IDe10843, 2010.
41. T. Kato,H. Shimano, T. Yamamoto et al., "Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets," Diabetes, vol. 57, no. 9, pp. 2382-2392, 2008.
42. K. Iizuka, H. Nakajima, M. Namba et al., "Metabolic consequence of long-term exposure of pancreatic cells to free fatty acid with special reference to glucose insensitivity," Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1586, no. 1, pp. 23-31, 2002.
43. E. Hu, E. Dul,C.-M. Sung et al., "Identification of novel isoformselective inhibitors within class I histone deacetylases," Journal of Pharmacology and ExperimentalTherapeutics, vol. 307, no. 2, pp. 720-728, 2003.
44. P. Karagianni and J. Wong, "HDAC3: taking the SMRT-NCoRrect road to repression," Oncogene, vol. 26,no. 37, pp. 5439-5449, 2007.
45. D. P. Christensen, M. Dahllöf, M. Lundh et al., "Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus,"MolecularMedicine, vol. 17, no. 5-6, pp. 378-390, 2011.
46. Z. Gao, J. Yin, J. Zhang et al., "Butyrate improves insulin sensitivity and increases energy expenditure in mice," Diabetes, vol. 58, no. 7, pp. 1509-1517, 2009.
47. A. Galmozzi, N. Mitro, A. Ferrari et al., "Inhibition of class i histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue," Diabetes, vol. 62, no. 3, pp. 732-742, 2013.
48. L. Larsen,M. Tonnesen, S. G. Ronn et al., "Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells," Diabetologia, vol. 50, no. 4, pp. 779-789, 2007.
49. B. C. Meier and B. K. Wagner, "Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics," Epigenomics, vol. 6, no. 2, pp. 209-214, 2014.